An Open-label Study to Find the Minimum Inhibitory Concentration(MIC) of KAE609 in Adult Male Patients With Acute, Uncomplicated Malaria Due to Plasmodium Falciparum Monoinfection

Trial Profile

An Open-label Study to Find the Minimum Inhibitory Concentration(MIC) of KAE609 in Adult Male Patients With Acute, Uncomplicated Malaria Due to Plasmodium Falciparum Monoinfection

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Cipargamin (Primary)
  • Indications Falciparum malaria
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 13 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 01 Dec 2014 Planned End Date changed from 1 Jan 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top